Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSL ( (AU:CSL) ) has issued an update.
CSL Limited has announced an on-market buy-back of its ordinary fully paid shares. This strategic move is likely aimed at optimizing the company’s capital structure and potentially enhancing shareholder value. The buy-back could also signal the company’s confidence in its current market position and future prospects.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$293.83 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and manufacturing of innovative medicines and vaccines. The company is known for its contributions to global health, particularly in the areas of blood plasma products and influenza vaccines.
Average Trading Volume: 746,027
Technical Sentiment Signal: Buy
Current Market Cap: A$130.9B
For detailed information about CSL stock, go to TipRanks’ Stock Analysis page.